Mark J. Ratain to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Mark J. Ratain has written about Antineoplastic Agents, Immunological.
Connection Strength
1.625
-
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. J Clin Pharmacol. 2022 04; 62(4):532-540.
Score: 0.700
-
Dose Optimization of Pembrolizumab: Less May Be More. Clin Pharmacol Ther. 2022 05; 111(5):993.
Score: 0.696
-
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
Score: 0.161
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.035
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.033